JP MORGAN/CALL/VERTEX PHARMACEUTICALS/410/0.1/19.07.24 | Market Closed - Börse Stuttgart 08:07:46 25/06/2024 BST | ||
| 6.41 EUR | +14.26% |
|
| 1 month | +31.62% | ||
| 3 months | +85.26% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 6.41 | +14.26% |
| 24/06/24 | 5.61 | -5.08% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 08:07 am
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB778G |
| ISIN | DE000JB778G7 |
| Date issued | 22/11/2023 |
| Strike | 410 $ |
| Maturity | 19/07/2024 (18 Days) |
| Parity | 10 : 1 |
| Emission price | 1.5 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.31 € |
|---|---|
| Lowest since issue | 1.54 € |
| Delta | 0x |
| Omega | 0.000000 |
| Premium | 0x |
| Gearing | 0x |
| Moneyness | 1.161 |
| Difference Strike | -61.25 $ |
| Difference Strike % | -14.94% |
| Intrinsic value | 6.112 |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
471.2
USD
Average target price
468.3
USD
Spread / Average Target
-0.63%
- Stock Market
- Warrants
- Warrant
